Mallinckrodt to Buy Pain-Drug Maker Cadence for $1.3 Billion

Mallinckrodt Plc, the drugmaker spun off by Covidien Plc last year, agreed to buy Cadence Pharmaceuticals Inc. for about $1.3 billion in cash to add a pain treatment used in hospitals.